Comprehensive Analytical Strategies for Peptides Therapeutics and GLP-1 Agonist with Agilent
Peptide therapeutics have emerged as one of the fastest-growing classes of biomolecules, with GLP-1 agonists leading the way in advancing treatment options for metabolic and related disorders. Their rapid expansion underscores the need for comprehensive analytical strategies to ensure quality, safety, and efficacy across research, development, and manufacturing.
This presentation provides an overview of peptide therapeutics with a focus on analytical workflows that support their characterization and development. Topics include method development, peptide mapping, and advanced characterization approaches using Agilent’s Triple Quadrupole and High-Resolution Mass Spectrometry platforms. We will also highlight GLP-1 peptide analysis in quality control environments featuring Agilent’s InfinityLab LC Series and Single Quadrupole solutions. In addition, data analysis and management strategies leveraging Agilent SLIMS and compliance solutions will be discussed to demonstrate how integrated informatics streamline peptide workflows.
This session illustrates how Agilent’s instrumentation, consumables, and services are uniquely positioned to enable success throughout the biopharmaceutical value chain.
Presenter: Lauren Skrajewski-Schuler, PhD (Biopharma Workflow Specialist, Agilent Technologies, Inc.)
Lauren Skrajewski-Schuler, PhD, is a Biopharma Workflow Specialist at Agilent Technologies, helping researchers and biopharma teams maximize the impact of their analytical workflows. With expertise in peptide therapeutics and HPLC coupled with mass spectrometry, she helps customers optimize workflows and analyical strategies for peptide characterization, method development, and quality control—particularly for GLP-1 agonists. In this session, Lauren will share practical insights and tips for leveraging Agilent solutions to support every stage of the peptide development journey.
